Genetic and Experimental Evidence Identifies STMN1 as a Potential Therapeutic Target in Atherosclerosis
Journal of Cardiovascular Development and Disease · 27.10.2026 · 13 (11) · 544
DOI: 10.3390/jcdd13110544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 27.10.2026. Verfasst von Jiuxu Kan und 6 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key R&D Program of China, National Science and Technology Major Project, the State Key Program of National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
STMN1 regulates microtubule dynamics, cytoskeletal remodeling, and cell migration, but its role in atherosclerosis remains unclear. Methods: eQTL-based two-sample Mendelian randomization was used to assess associations between genetically predicted STMN1 expression and coronary or cerebral atherosclerosis. Functional validation was performed in high-cholesterol diet-fed ApoE−/− mice with AAV9-mediated STMN1 knockdown and in ox-LDL-treated mouse aortic smooth muscle cells with siRNA-mediated STMN1 silencing. Virtual screening was conducted to identify candidate STMN1-binding compounds.
Results
Higher genetically predicted STMN1 expression was associated with increased risk of both coronary and cerebral atherosclerosis. In vivo, STMN1 knockdown reduced aortic lesion burden, plaque lipid deposition, plaque area, and inflammatory cytokine expression, while increasing collagen content without significantly altering serum lipid levels. In vitro, STMN1 silencing suppressed ox-LDL-induced inflammation, migration, and MMP2/MMP9 expression. R428 was identified as the top-ranked candidate compound.
Conclusions
STMN1 may promote atherosclerosis by regulating vascular inflammation, smooth muscle cell migration, and matrix remodeling.
Förderung
- the National Key R&D Program of China
- National Science and Technology Major Project
- the State Key Program of National Natural Science Foundation of China
- Key Research and Development Plan of Heilongjiang Province
- Disciplinary Collaborative Innovation Achievements Project
- Natural Science Fund Research Team Project of Heilongjiang Provincial Department of Science and Technology
- Chinese Society of Cardiology's Foundation
Zitieren
APA
Kan, J., Wang, H., Wei, L., Wang, T., Pan, Z., Yu, L., & Li, Y. (2026). Genetic and Experimental Evidence Identifies STMN1 as a Potential Therapeutic Target in Atherosclerosis. Journal of Cardiovascular Development and Disease, 13(11), 544. https://doi.org/10.3390/jcdd13110544
Vancouver
Kan J, Wang H, Wei L, Wang T, Pan Z, Yu L, et al. Genetic and Experimental Evidence Identifies STMN1 as a Potential Therapeutic Target in Atherosclerosis. Journal of Cardiovascular Development and Disease. 2026;13(11):544. doi:10.3390/jcdd13110544
BibTeX
@article{Kan2026,
author = {Kan, Jiuxu and Wang, Hong and Wei, Licheng and Wang, Tengyu and Pan, Zhenwei and Yu, Luyang and Li, Yue},
title = {Genetic and Experimental Evidence Identifies STMN1 as a Potential Therapeutic Target in Atherosclerosis},
journal = {Journal of Cardiovascular Development and Disease},
year = {2026},
volume = {13},
number = {11},
pages = {544},
doi = {10.3390/jcdd13110544}
}
EUVIMED